In the pathological progression of Alzheimer’s Disease (AD), plasma p-Tau217 is proven to be the most specific and earliest detectable biomarker. Capturing this biomarker allows healthcare providers to identify neurodegenerative pathology 10 to 20 years before clinical cognitive decline manifests.
To unlock advanced testing capabilities for modern laboratories, the Human phosphorylated Tau217 detection kit (Digital Immunochip Method) developed by iomics and officially distributed by DOIT Scientific JSC offers the ultimate alternative: highly accurate, safe, and completely non-invasive early screening.
MAXIMIZING PATIENT COMFORT AND SAFETY
Historically, capturing reliable Alzheimer’s biomarkers relied on traditional methods carrying significant constraints:
- Cerebrospinal Fluid (CSF) Lumbar Punctures: Highly invasive, painful, and prone to clinical complications in elderly patients.
- PET Scans: Cost-prohibitive, logistically complex, and difficult to deploy for routine screening.
The emergence of this p-Tau217 single-molecule immunoassay kit completely solves these limitations. Executed via a single blood sample (Human Plasma), the collection process is quick, gentle, and safe, substantially reducing patient discomfort while delivering absolute clinical data integrity.
OUTSTANDING ACCURACY POWERED BY DIGITAL IMMUNOCHIP TECH
This detection kit establishes its technological edge by integrating state-of-the-art molecular immunoassay platforms:
- CSF-Equivalent Accuracy: Robust clinical validation demonstrates that plasma p-Tau217 quantification achieves accurate results equivalent to invasive CSF analysis.
- Proprietary Molecular Counting Mechanism: The kit utilizes a highly specific dual-antibody sandwich methodology coupled with magnetic beads. An advanced CCD detector isolates, validates, and counts individual target protein molecules with absolute precision.
- Synergized Performance with Inspirer DX: When operated concurrently on the Inspirer DX Analyzer, the system yields 1,000x greater sensitivity compared to conventional ELISA techniques, effortlessly reaching femtogram-level limits of detection.
CLINICAL AND RESEARCH APPLICATIONS
- Supporting Clinical Diagnosis: Acts as a vital tool for clinicians providing adjunct screening and diagnostic support for Alzheimer’s Disease at pre-clinical stages.
- Differential Diagnosis: Empowers medical teams to confidently differentiate Alzheimer’s from other complex dementia profiles.
- Research & Development (R&D): Offers high-precision measurement assets for monitoring disease trajectory and evaluating clinical efficacy in pharmaceutical R&D pipelines.
TECHNICAL SPECIFICATIONS
- Product Name: Human phosphorylated Tau217 protein detection kit (digital immunochip method).
- Developer: iomics Biosciences.
- Authorized Distributor: DOIT Scientific JSC.
- Packaging Configurations: 48 tests/box or 96 tests/box.
- Sample Requirements: Human Plasma.
- Compatible Platform: Inspirer DX Analyzer.
COMMERCIAL INQUIRIES & PARTNERSHIPS
DOIT Scientific JSC is a premier provider of advanced biotechnology solutions in Vietnam. We are dedicated to supporting hospitals, research centers, and diagnostic labs with genuine products, rigorous technical dossiers, and optimized commercial frameworks.
For further technical data sheets, catalogs, or commercial quotes, please contact us:
- Hotline: (+84) 988.01.68.01
- Email: info@doitvn.com
- Address: No. 645, Group 39, Zone 4, Ha Lam Ward, Quang Ninh Province, Vietnam.
